| pubmed-article:2551304 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2551304 | lifeskim:mentions | umls-concept:C1267092 | lld:lifeskim |
| pubmed-article:2551304 | lifeskim:mentions | umls-concept:C0000477 | lld:lifeskim |
| pubmed-article:2551304 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2551304 | lifeskim:mentions | umls-concept:C0260043 | lld:lifeskim |
| pubmed-article:2551304 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:2551304 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:2551304 | pubmed:dateCreated | 1989-10-26 | lld:pubmed |
| pubmed-article:2551304 | pubmed:abstractText | The effects of new 4-aminopyridine (4-AP) derivatives were investigated in the isolated mouse phrenic nerve-hemidiaphragm preparation under single impulse stimulation and tetanic conditions. The basic 4-AP structure was modified in position 3 on the pyridine nucleus by introducing different substituents. Results were compared to those obtained with 4-AP and 3,4-diaminopyridine. The compounds were tested for their antagonistic effect against calcium antagonists and botulinum toxin A. The effect on smooth muscle was investigated on the isolated guinea-pig ileum. Physico-chemical parameters of the test compounds were determined by the partition coefficient and ionization constant. Finally structure-activity relationship analysis revealed that the activity was highly related to lipophilicity and the steric volume. So far 4-AP itself provided the most advantageous molecular structure. | lld:pubmed |
| pubmed-article:2551304 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2551304 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2551304 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2551304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2551304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2551304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2551304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2551304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2551304 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2551304 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:2551304 | pubmed:issn | 0004-4172 | lld:pubmed |
| pubmed-article:2551304 | pubmed:author | pubmed-author:WaserP GPG | lld:pubmed |
| pubmed-article:2551304 | pubmed:author | pubmed-author:HofmannAA | lld:pubmed |
| pubmed-article:2551304 | pubmed:author | pubmed-author:BergerS GSG | lld:pubmed |
| pubmed-article:2551304 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2551304 | pubmed:volume | 39 | lld:pubmed |
| pubmed-article:2551304 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2551304 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2551304 | pubmed:pagination | 762-5 | lld:pubmed |
| pubmed-article:2551304 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:meshHeading | pubmed-meshheading:2551304-... | lld:pubmed |
| pubmed-article:2551304 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2551304 | pubmed:articleTitle | Effects of new 4-aminopyridine derivatives on neuromuscular transmission and on smooth muscle contractility. | lld:pubmed |
| pubmed-article:2551304 | pubmed:affiliation | Institute of Pharmacology, University of Zurich, Switzerland. | lld:pubmed |
| pubmed-article:2551304 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2551304 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2551304 | lld:pubmed |
